Prosecution Insights
Last updated: May 29, 2026
Application No. 18/209,894

METHOD FOR PREPARING CHIRAL MALEIMIDE DERIVATIVES USING ORGANIC CHIRAL CATALYST COMPOUNDS AND ECO-FRIENDLY SOLVENTS

Non-Final OA §103
Filed
Jun 14, 2023
Priority
Aug 12, 2022 — RE 10-2022-0101243
Examiner
SHAMEEM, GOLAM M
Art Unit
1621
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Korea University Research And Business Foundation
OA Round
1 (Non-Final)
87%
Grant Probability
Favorable
1-2
OA Rounds
0m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 87% — above average
87%
Career Allowance Rate
768 granted / 884 resolved
+26.9% vs TC avg
Strong +16% interview lift
Without
With
+16.0%
Interview Lift
resolved cases with interview
Fast prosecutor
1y 10m
Avg Prosecution
24 currently pending
Career history
897
Total Applications
across all art units

Statute-Specific Performance

§101
0.5%
-39.5% vs TC avg
§103
3.2%
-36.8% vs TC avg
§102
6.1%
-33.9% vs TC avg
§112
12.5%
-27.5% vs TC avg
Black line = Tech Center average estimate • Based on career data from 884 resolved cases

Office Action

§103
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION Priority This application claims benefit for foreign priority under 35 U.S.C. § 119(a)-(d) to PNG media_image1.png 20 310 media_image1.png Greyscale , however the certified copy of priority document (with English language translation) has not been received or made part of the file. Therefore, any priority claim to this document has not been perfected. Status of Claims Claims 1-15 are currently pending in the application. Receipt is acknowledged of amendment / response filed on November 04, 2025 and that has been entered. Information Disclosure Statement Receipt is acknowledged of Information Disclosure Statement (IDS), filed on 07/22/2024, which has been entered in the file. Response to Election/Restriction In response to the restriction requirement, Applicants have elected Group I, which includes claims 1-10, drawn to a method for preparing chiral maleimide derivatives thereof, and the elected species as set forth and found to a Compound of Formula 3, such as, PNG media_image2.png 158 288 media_image2.png Greyscale , without traverse, is acknowledged. Claims 11-15 are withdrawn from further consideration pursuant to 37 C.F.R. 1.142 (b) as being drawn to a non-elected subject matters and therefore, the requirement for restriction is still deemed proper made it final. Applicants preserve their right to file a divisional on the non-elected subject matter. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. § 103(a), which forms the basis for all obviousness rejections, set forth in this Office action: (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negative by the manner in which the invention was made. Claims 1-10 are rejected under 35 U.S.C. § 103(a) as being unpatentable over Shim et al (Molecules, 2022, IDS) and further in view of Kokotos (Organic Letters, 2013, IDS). Applicant claims a method for preparing chiral maleimide derivatives thereof. Determination of the scope and content of the prior art (MPEP §2141.01) Shim et al (2022) teaches a similar process for the preparation of Maleimide utilizing analogous reagents and reaction conditions [such as, PNG media_image3.png 90 354 media_image3.png Greyscale , see Table 1, page 3]. Kokotos (2013) also teaches a similar process having an asymmetric Michael Addition reaction of aldehydes to Maleimide (see abstract and whole reference). Ascertainment of the difference between the prior art and the claims (MPEP §2141.02) The difference between the process taught in the references and the claimed process herein lies merely in the variation of reagents and reaction conditions such as, the use of water instead of organic solvent (e.g., chloroform or dichloromethane, Shim et al page 2, line 6) under specific set of reaction conditions in order to obtain the chiral Maleimide derivatives for instantly claimed inventions. Further, the disclosure of Kokotos (2013) that teaches the substrate scope of the Michael Addition (see Table 2, page 2408) reaction for the synthesis of Maleimide derivatives that would easily place Applicants invention in possession of the public at the time of Applicants invention was filed. The differences between the instant claims and the prior art references are so negligible, that one of ordinary skill in the chemical arts would expect slight variations to be within the expected purview of 35 U.S.C. 103(a). Finding of prima facie obviousness--rational and motivation (MPEP §2142-2413) It is obvious to prepare compounds by an old method using analogous starting materials and determining the optimum reaction conditions in the absence of any unobvious or unexpected results. The motivation to make the claimed process / method derives from the expectation that the use of analogous reactants / reagents (e.g., use of thiourea based catalyst, PNG media_image4.png 138 258 media_image4.png Greyscale , Shim et al page 2, line 1)and reaction conditions would have made similar yield of product. The selection of reaction conditions is more optimization by more modification of routine experimentation and within one skilled in the art (In re Aller, et al., 105 USPQ 233). Since there is an exemplary teaching in the prior art to obtain the instantly claimed method, it is obvious for those ordinary skilled in the chemical art with a reasonable expectation of success that such modification and optimization of reaction conditions would give process with similar rate of recovery. Therefore, in looking at the instantly claimed method as a whole, the claimed method would have been suggested to one skilled in the art and therefore, is obvious, absent evidence to the contrary. Telephone Inquiry Any inquiry concerning this communication or earlier communications from the examiner should be directed to Golam Shameem, Ph.D. whose telephone number is (571) 272-0706. The examiner can normally be reached on Monday-Thursday from 7:30 AM - 6:00 PM. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Clinton Brooks, Ph.D. can be reached at (571) 270-7682. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://portal.uspto.gov/external/portal. Should you have questions about access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist, whose telephone number is (571) 272-1600. /GOLAM M SHAMEEM/Primary Examiner, Art Unit 1621
Read full office action

Prosecution Timeline

Jun 14, 2023
Application Filed
Jan 20, 2026
Non-Final Rejection mailed — §103
Apr 20, 2026
Response Filed

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12637439
PREPARATION OF CANNABICHROMENE AND RELATED CANNABINOIDS
3y 11m to grant Granted May 26, 2026
Patent 12636284
COMPOSITIONS FOR USE IN THE PREVENTION AND/ OR TREATMENT OF INTELLECTUAL DISABILITY AND NEURODEGENERATIVE DISEASES IN A SUBJECT WITH DOWN SYNDROME
2y 6m to grant Granted May 26, 2026
Patent 12630506
DIRECT THROMBIN INHIBITORS AND METHODS OF USE THEREOF
3y 7m to grant Granted May 19, 2026
Patent 12630516
NOVEL COMPOUNDS
3y 2m to grant Granted May 19, 2026
Patent 12630508
METHOD FOR MANUFACTURING HETEROCYCLE-CONTAINING AMINO ACID COMPOUND
2y 10m to grant Granted May 19, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
87%
Grant Probability
99%
With Interview (+16.0%)
1y 10m (~0m remaining)
Median Time to Grant
Low
PTA Risk
Based on 884 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month